FDA approves cancer-killing cold sore virus as therapy for late-stage melanoma

October 28, 2015, University of Utah Health Sciences
Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0

The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer that can be difficult to treat.

The approval came as the result of a recent Phase III study, which showed that more patients with late-stage melanoma, treated with a herpes cold sore virus designed to kill , had a better response when compared to a different treatment. Robert Andtbacka, M.D., from Huntsman Cancer Institute at the University of Utah and Howard L. Kaufman, M.D., from Rutgers Cancer Institute of New Jersey, led the multisite study, published May 26 online in the Journal of Clinical Oncology.

According to Andtbacka, "The goal of this targeted therapy is to treat late stage patients more effectively and with fewer side effects."

The researchers employed a genetically modified herpes virus, made by the pharmaceutical company Amgen, which was designed to replicate inside tumors and kill them. In addition, the virus contains a human gene to make granulocyte macrophage colony-stimulating factor (GM-CSF) with the goal of causing an anti-tumor immune response in the patient.

Frequently, tumor cells evade the immune system, but Andtbacka says the therapy was developed to retrain the immune system to recognize the melanoma as something that shouldn't be there. "Not only are the injected tumor cells destroyed, but the is activated to fight the melanoma not only where we injected it, but also at distant sites."

In the clinical trial, patients with Stage IIIB, IIIC, or IV melanoma were randomized to receive either the virus therapy talimogene laherparepvec (T-VEC) injected directly into their tumors or to receive an injection of GM-CSF under the skin.

The researchers observed that T-VEC virus immunotherapy caused tumors to shrink compared to treatment with GM-CSF alone: 16 percent of T-VEC treated participants (n = 295) experienced a durable response, meaning that their tumors shrank for >6 months, relative to 2 percent of the GM-CSF alone group (n = 141). While patients' lifespans, on average, were only extended by a small amount (4.4 months), 32 (11 percent) of the T-VEC recipients and one GM-CSF recipient (<1 percent), showed no signs of cancer after treatment.

Both local and systemic immune responses after treatment with T-VEC were also observed by the researchers, supporting the idea that combining T-VEC with other immunotherapies might further increase effectiveness. Studies testing such combination therapies are currently underway.

Andtbacka says the most common adverse effects of the T-VEC treatment were modest, consisting of flu-like symptoms, such as fatigue, chills, nausea, and injection-site reactions. Although more severe adverse effects did occur in some patients, the only one occurring in > 2 percent of T-VEC treated patients was cellulitis, a potentially dangerous skin infection (2.1 percent). "This safety profile is encouraging, since this is the first randomized trial of an oncolytic virus in patients with cancer," says Andtbacka.

T-VEC represents a novel treatment option for with injectable metastatic melanoma. This collaborative work was enabled by Amgen, manufacturer of the T-VEC and will be marketed under the name IMLYGICTM.

FDA approves first-of-its-kind product for the treatment of : http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469571.htm

Explore further: FDA approves drug that uses herpes virus to fight cancer

Related Stories

FDA approves drug that uses herpes virus to fight cancer

October 27, 2015
Federal health officials on Tuesday approved a first-of-a-kind drug that uses the herpes virus to infiltrate and destroy deadly skin cancer tumors.

World first as viral immunotherapy for skin cancer shows patient benefit in phase III trial

May 26, 2015
A genetically engineered herpes virus can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action against tumours, a landmark clinical trial has shown.

Novel Amgen virus-vaccine shrinks melanoma tumors

March 20, 2013
Shares of drugmaker Amgen Inc. are rising on news its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test.

Combining radiation with immunotherapy showing promise against melanoma

May 19, 2016
Combining radiation treatments with a new generation of immunotherapies is showing promise as a one-two-punch against melanoma, Loyola Medicine researchers report in the Journal of Radiation Oncology.

Drug shows promise against rare, aggressive skin cancer

April 19, 2016
(HealthDay)—A newer drug that boosts the immune system's ability to kill tumor cells may help people with a rare, aggressive form of skin cancer, a preliminary study suggests.

Fast-acting virus targets melanoma in mice

June 17, 2013
(Medical Xpress)—Yale researchers eradicated most melanoma tumors by exposing them to a fast-acting virus, they report in the June 15 edition of the Journal of Virology.

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.